The Development Of Rosmarinic Acid Derivatives To Target Il17a In Glioblastoma Multiforme Via Angiogenic Pathways

Simple item page
dc.contributor.authorKhan, Md Shamsuddin Sultan
dc.date.accessioned2020-10-22T08:08:43Z
dc.date.available2020-10-22T08:08:43Z
dc.date.issued2017-09
dc.description.abstractIn this study, glioblastoma inhibition was acheived via the disruption of IL17A, which blocks angiogenesis using new derivatives of rosmarinic acid (RA). Anti-GBM activity of the compounds were determined through cell migration and cell proliferation assays with U87 MG, DBTRG MG, and EA.hy 926 cells. Antiangiogenic activity was investigated with tube formation, CAM, and aortic explant assays. The compounds’ activity in IL17A and VEGF expression was determined using ELISA and their apoptotic activity was assessed by the Caspase assay. The cancer pathway was determined using the reporter gene assay.en_US
dc.identifier.urihttp://hdl.handle.net/123456789/10564
dc.language.isoenen_US
dc.publisherUniversiti Sains Malaysiaen_US
dc.subjectDevelopment Of Rosmarinic Acid Derivativesen_US
dc.subjectTarget Il17a In Glioblastoma Multiformeen_US
dc.subjectVia Angiogenic Pathwaysen_US
dc.titleThe Development Of Rosmarinic Acid Derivatives To Target Il17a In Glioblastoma Multiforme Via Angiogenic Pathwaysen_US
dc.typeThesisen_US
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pusat Pengajian Sains Kimia - Tesis